Fed. Circ. Grants Last-Minute Pause Of ITC's Botox Rival Ban

By Tiffany Hu · February 16, 2021, 9:44 PM EST

South Korean-based Daewoong Pharmaceuticals can keep its low-cost version of Allergan's Botox treatment on the market while the Federal Circuit considers whether it should pause the U.S. International Trade Commission's import...

To view the full article, register now.


Featured Stories

February Roundup: Retaliation, Trans Bias, Natural Hair No Photo Available

The California Supreme Court accepted the Ninth Circuit's invitation to clarify the legal bar plaintiffs must clear to sue for retalia... (more story)

NLRB's 1st Black Chair Says Board Must Tackle Racial Equity No Photo Available

The National Labor Relations Board has come a long way since its founding in 1935 as the legal body in the United States that confront... (more story)

3 Takeaways From 9th Circ. Virgin Flight Attendants Ruling No Photo Available

Airlines will face stiffer headwinds navigating various state rules on flight crew hours now that the Ninth Circuit has upheld Califor... (more story)